Show simple item record

dc.contributor.authorWu, H.
dc.contributor.authorSriuranpong, V.
dc.contributor.authorPonce Aix, S.
dc.contributor.authorAscierto, P. A.
dc.contributor.authorFasolo, A.
dc.contributor.authorSezer, A.
dc.contributor.authorKowalski, D. M.
dc.contributor.authorFaris, J. E.
dc.contributor.authorCameron, S.
dc.contributor.authorMataraza, J.
dc.contributor.authorGarrido Lopez, P.
dc.contributor.authorAntona, V.
dc.contributor.authorOchoa de Olza, M.
dc.contributor.authorOzguroglu, M.
dc.contributor.authorLin, C-C.
dc.contributor.authorTaylor, M.
dc.contributor.authorBoni, V.
dc.contributor.authorBrunsvig, P. F.
dc.contributor.authorGeater, S. L.
dc.contributor.authorSalvagni, S.
dc.date.accessioned2021-03-05T19:40:28Z
dc.date.available2021-03-05T19:40:28Z
dc.identifier.citationLin C., Taylor M., Boni V., Brunsvig P. F. , Geater S. L. , Salvagni S., Garrido Lopez P., Ozguroglu M., Sriuranpong V., Ponce Aix S., et al., "Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer", 43rd ESMO Congress (ESMO), Munich, Almanya, 19 - 23 Ekim 2018, cilt.29, ss.413
dc.identifier.othervv_1032021
dc.identifier.otherav_d0566ced-1994-47f4-857d-63e180afe56c
dc.identifier.urihttp://hdl.handle.net/20.500.12627/137745
dc.language.isoeng
dc.subjectDahili Tıp Bilimleri
dc.subjectOnkoloji
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectİç Hastalıkları
dc.subjectONKOLOJİ
dc.titlePhase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer
dc.typeBildiri
dc.contributor.departmentNational Taiwan University , ,
dc.identifier.volume29
dc.contributor.firstauthorID155102


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record